drugset / Trial / NCT00496509

Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

NCT00496509

Phase 1 Completed 24 enrolled Genzyme, a Sanofi Company
RandomizedSingle-groupOpen-labelTreatment

Summary

A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.

Timeline

Start
2006-08
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 100 mg
Subject Vandetanib Small molecule 300 mg

Indications